Login

Research Materials

National Disease Research Interchange
Biomedical Research Materials for Research into Fanconi Anemia

Background:
To facilitate collection of biomedical research materials for FA research, the Fanconi Anemia Research Fund has entered into a partnership with the National Disease Research Interchange (NDRI). NDRI is a 501(c)(3) not-for-profit organization with over 25 years experience in obtaining, storing and distributing human cells, tissues and organs to researchers and scientists (<a href="http://www.ndriresource.org/">www.ndriresource.org</a>). In conjunction with the NIH Office of Rare Diseases, in 2002 NDRI began to develop a program focused on the unmet needs of the rare disease research community for human organs and tissues. NDRI receives funding for its Rare Disease Program from the National Institutes of Health and the Office of Rare Diseases.

Available Research Materials:
Biomedical samples of Fanconi anemia are available to researchers. Given the rarity of FA, the supply of some biomedical research materials is occasionally limited. Samples are provided only to those researchers who are specifically studying FA. In general, NDRI places around 20,000 biospecimens annually with researchers in academic and government laboratories, as well as those in biomedical and pharmaceutical industries. To that end, the organization works with organ procurement organizations, eye banks, tissue banks and major medical centers in the United States. NDRI has also developed unique programs to serve researchers studying rare diseases, such as Fanconi anemia. Importantly, NDRI has developed mechanisms to aseptically obtain tissues with a very short death-to-preservation interval, making them ideal for cell culture, genomic and proteomic research. NDRI also serves the cancer research community with tumor and normal adjacent tissue specimens preserved at 4°C, frozen, snap-frozen or formalin-fixed/paraffin embedded.

NDRI will strive to meet your exact needs for FA research. Please visit www.ndriresource.org to learn how NDRI can be a valuable resource for your research. To receive an application, contact a Rare Disease Coordinator at raredisease@ndriresource.org or by phone at 1-800-222-6374. The application is also available on NDRI’s website under the Quick Links section.

FA Antibody Project: Antisera Now Available Against Fanconi Anemia Complementation Group Proteins

FARF has sponsored the development of high-titer, affinity-purified rabbit polyclonal antisera against the Fanconi anemia complementation group proteins in order to facilitate research on Fanconi anemia.

Affinity-purified antisera are currently available against the following FANC proteins: FANCA, B, C, D1(BRCA2), D2, E, F, G(XRCC9), I, J(BRIP1/BACH1), M, N(PALB2), O(RAD51C), P(SLX4) and the deubiquitinating enzyme USP1. In addition to affinity-purified antisera, unpurified sera are available for many FANC proteins for investigators interested in trying alternative purification approaches.

The FA Cell Repository has immortalized human FA fibroblast cell lines for complementation groups FANCA, FANCC, FANCD2, and FANCG, as well as immortalized mouse embryonic fibroblasts (MEFs) from knock out mice of the following genotypes: Fanca, Fancc, Fancd2, Fanca/c, Aldh2 and Fancd2/Aldh2.

Investigators requesting antisera or cell lines must complete a request via the website http://www.ohsu.edu/research/fanconi-anemia/index.cfm and be willing to meet FARF’s use agreement. We depend critically on user feedback on antisera, so will require this as well from all end-users.

General inquiries contact: Ray Monnat, MD, University of Washington, Seattle, Wash.
Telephone: 206-616-7392; Email: monnat@u.washington.edu

Antibody distribution contact: Leslie Wakefield, Oregon Health & Science University, Portland, Ore.
Telephone: 503-494-6889; Email: wakefiel@ohsu.edu

of note

Submit your abstract for the 2017 FA Symposium! learn more...

We are pleased to welcome Mark Quinlan to the FARF team as Executive Director learn more...

Five Fanconi Anemia Projects Funded in Last Year Thanks to Knight Family learn more...